WHY PARTNER WITH SEQIRUS?
Innovation has been in our DNA for more than a century. We have the full spectrum of strengths from research and clinical development to manufacturing and commercialisation in influenza vaccines. We know that partnerships can accelerate innovation and we work closely with organisations outside our walls that have unique technologies to develop new transformative approaches to influenza protection.
Seqirus is a fully integrated biotechnology company with global manufacturing and commercial operations for influenza vaccines, with facilities in the US, UK and Australia. Our approach is to collaborate with industry, academia or other groups developing great products and technologies that have the capacity to address unmet public health need. We will work to find mutually beneficial arrangements that include traditional licensing, joint ventures, strategic investments or other suitable structures that most effectively leverage our combined capabilities.
Seqirus also in-licenses a wide range of pharmaceutical and vaccine products from international partners for distribution in Australia and New Zealand and has a dedicated professional team who can offer flexible partnering solutions from regulatory to commercialisation.
Investigator Initiated Studies
Investigator initiated studies are research projects initiated and managed by a researcher external to Seqirus.
Contact Medical Affairs in your local country.
Collaboration can accelerate the innovation of new life-saving vaccines.
Pandemic Response SolutionsTM
As a global leader in influenza vaccine manufacturing, Seqirus offers a portfolio of pandemic vaccines and services which are tailored to rapid response.
Pandemic Influenza Preparedness
Seqirus’ state-of-the art Holly Springs facility in North Carolina was purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to combat pandemic influenza threats *. BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.In 2017, Seqirus celebrated the 10th year anniversary of our partnership BARDA. Through this partnership, Seqirus has continued to advanced cell-based technology and production output. Our commitment is to supply the US Government with 150 million doses of pandemic influenza vaccine within 6 months of a declaration of a pandemic.
* This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract numbers HHSO100200600012C, HHSO100200700030C, HHSO100200900101C and HHSO100201200003I.
Improving access to antivenom in Papua New Guinea
A government and industry partnership designed to help save the lives of people bitten by venomous snakes in Papua New Guinea (PNG). The project will significantly improve access to antivenoms in PNG by combining a large annual donation of antivenom with a purpose-built distribution and monitoring system.Learn more
Our Global Health Partnerships
“The burden and impact of influenza remains an important global healthcare concern and ensuring we have effective vaccines is a public health imperative,” says Gordon Naylor, Seqirus’ inaugural leader. “As a company on the front line of influenza protection, we are committed to developing innovative solutions and to working with partners around the world to help reduce deaths and severe illness caused by influenza.”
WHO Pandemic Influenza Preparedness Framework
Seqirus supports the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework which aims to improve the sharing of influenza viruses with pandemic potential and the equitable access to products necessary to respond to an influenza pandemic including vaccines, antivirals and diagnostics. Seqirus makes an annual financial contribution and has also committed 10% of influenza vaccine output in real time to the WHO for deployment to developing countries in the event of a pandemic emergency.
The Global Initiative on Sharing All Influenza Data (GISAID), a non-profit organization and public-private partnership is recognised as the world’s foremost global collaboration of scientists and governments, from developed and developing countries, to promote the near-real time exchange and analysis of data on the ever-changing influenza viruses that threaten global populations. Seqirus is the first vaccine company to donate funds to help bolster GISAID’s efforts in bioinformatics and strengthen understanding of the impact on influenza.
The Human Vaccines Project
The Human Vaccines Project is a nonprofit public-private partnership focused on decoding the immune system to improve human health. Seqirus has joined the Project’s Universal Influenza Vaccine Initiative (UIVI), a collaboration of leading global organisations and partners working together to rapidly accelerate the development of a universal influenza vaccine that produces long lasting protection against seasonal and pandemic influenza.
UK/FLU/0519/0080 August 2019